Greg Behar News Today

Kovacs enhances Westwood’s equity solutions, focusing on tech-driven investment advisory services ...

25.04.2024 - Westwood Holdings Group, an investment management boutique and wealth management firm focused on U.S. Value, Multi-Asset, Real Assets, Alternatives and Custom Investment Solutions, announces the addition of Michael Kovacs as a senior solutions ...

(Bloomberg) -- Nestle SA is working on products designed to complement a new class of weight-loss drugs after revenue growth decelerated to the weakest pace in almost three years.Most Read from BloombergRinggit Falls to 25-Year Low, the Worst Performer in Asia After Yen This YearTesla Tempers Growth Expectations as Musk Sees Storm AheadWhere Does Israel Get Its 220,000 Barrels of Oil Every Day?Biden Vows Aid for Gaza, Backs Israel Over Hospital BlastQQQ Advances in Late Trading as Tesla Rebounds

[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) .............   Changes in the...

Nestlé Health Science's CEO is leaving end of year, with another company leader moving into the role.

By David Sachs Nestle said Friday that Greg Behar, chief executive officer of its food sciences arm, will leave at the end of the year. The Swiss food...

Greg Behar, the chief executive of Nestlé Health Science, has stepped down from the position. Anna Mohl will succeed Behar in the role.

Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company.

Peanut allergy treatment business divested to Stallergenes Greer.

Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic.